A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells

Cancer Immunology, Immunotherapy

Volumn 61, Issue 4, 2012, Pages 497-509

  Thakur, Archana ^a,b   Schalk, Dana ^a,b   Sarkar, Sanila H ^b   Al Khadimi, Zaid ^a,b   Sarkar, Fazlul H ^b   Lum, Lawrence G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

3D culture model; Activated T cells; Bispecific antibody; Breast cancer; Myeloid derived suppressor cells; Peripheral blood mononuclear cells

Indexed keywords

BISPECIFIC ANTIBODY; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INTERLEUKIN 2;

ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL KILLING; CELL SIZE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; ENRICHMENT CULTURE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANTIBODIES, BISPECIFIC; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MYELOID CELLS; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH1-TH2 BALANCE; TUMOR MICROENVIRONMENT;

EID: 84862500053     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1116-1     Document Type: Article

References (41)

1. Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5(8):641-654 (Pubitemid 41113195)
2. Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68(8):2561-2563 (Pubitemid 351556251)
3. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162-174
4. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162-179 (Pubitemid 351430364)
5. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast Rev 25(3):315-322 (Pubitemid 44922352)
6. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444
7. Sakaguchi S, Sakaguchi N, Shimizu J et al (2001) Immunologic tolerance maintained by CD25(+) CD4(+) regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32 (Pubitemid 33070205)
8. Gallina G, Dolcetti L, Serafini P et al (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8(+) T cells. J Clin Invest 116(10):2777-2790 (Pubitemid 44511641)
9. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16(1):53-65 (Pubitemid 43139709)
10. Ko JS, Bukowski RM, Fincke JH (2009) Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep 11(2): 87-93
11. Morse MA, Hall JR, Plate JMD (2009) Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther 9(3):331-339
12. Kusmartsev S, Gabrilovich DI (2002) Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51(6):293-298 (Pubitemid 34743981)
13. Kusmartsev S, Gabrilovich DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metast Rev 25(3):323-331 (Pubitemid 44922353)
14. Bronte V, Serafini P, Apolloni E, Zanovello P (2001) Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 24(6):431-446 (Pubitemid 33104863)
15. Bronte V, Chappell DB, Apolloni E et al (1999) Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8(+) T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162(10):5728-5737 (Pubitemid 29314923)
16. Menetrier-Caux C, Montmain G, Dieu MC et al (1998) Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92(12):4778-4791 (Pubitemid 29005881)
17. Peranzoni E, Zilio S, Marigo I et al (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22(2):238-244
18. Nefedova Y, Huang M, Kusmartsev S et al (2004) Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172(1):464-474 (Pubitemid 38020502)
19. Davol PA, Gall JM, Grabert RC et al. (2004) Infusions of T cells armed with anti-CD3 x anti-her2/neu bispecific antibody modulate in vivo patient immune responses in phase I clinical trials for breast and hormone refractory prostate cancers. Blood 104(11): 379a. (11-16-2004. Ref Type: Abstract)
20. Grabert RC, Cousens LP, Smith JA et al (2006) Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 12(2):569-576 (Pubitemid 43166151)
21. Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV et al (2001) Use of anti-CD3 x anti-HER2/neu bi-specific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu tumors. J Hematother Stem Cell Res 10:247-260 (Pubitemid 32423549)
22. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4(4):359-365 (Pubitemid 46766981)
23. Marigo I, Bosio E, Solito S et al (2010) Tumor-induced tolerance and immune suppression depend on the C/EBP beta transcription factor. Immunity 32(6):790-802
24. Elkabets M, Ribeiro VSG, Dinarello CA et al (2010) IL-1 beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 40(12): 3347-3357
25. Tu S, Bhagat G, Cui G et al (2008) Overexpression of interleukin-1 beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14(5): 408-419
26. Loetscher M, Gerber B, Loetscher P et al (1996) Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184(3):963-969
27. Yoshie O, Imai T, Nomiyama H (2001) Chemokines in immunity. Adv Immunol 78:57-110 (Pubitemid 32566018)
28. Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226-244
29. Conti I, Rollins BJ (2004) CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14(3):149-154 (Pubitemid 38586739)
30. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9(7):556-562 (Pubitemid 47121829)
31. Hasegawa H, Inoue A, Muraoka M, Yamanouchi J, Miyazaki T, Yasukawa M (2007) Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4(+)CD25(+) regulatory T cells in MRL/lpr mice. Arthr Res Ther 9(1):1-12
32. Huang B, Lei Z, Zhao J et al (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252(1):86-92 (Pubitemid 46734559)
33. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2): 137-148 (Pubitemid 39094044)
34. Mullins DW, Anderson SG, Mayer ME et al (2004) Chemokine receptor expression patterns on activated CD8(+) T lymphocytes correlate with survival in melanoma patients receiving peptide-based immunotherapy. FASEB J 18(4):A64-A65
35. Mullins IM, Slingluff CL, Lee JK et al (2004) CXC chemokine receptor 3 expression by activated CD8(+) T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 64(21):7697-7701 (Pubitemid 39446899)
36. Harlin H, Meng Y, Peterson AC et al (2009) Chemokine expression in melanoma metastases associated with CD8(+) T-cell recruitment. Cancer Res 69(7):3077-3085
37. Liu YQ, Poon RT, Hughes J, Feng XQ, Yu WC, Fan ST (2005) Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma. Clin Immunol 114(2):174-182 (Pubitemid 40082383)
38. Shin EC, Shin WC, Choi Y, Kim H, Park JH, Kim SJ (2001) Effect of interferon-gamma on the susceptibility to Fas (CD95/APO-1)-mediated cell death in human hepatoma cells. Cancer Immunol Immunother 50(1):23-30 (Pubitemid 32250043)
39. Selleck WA, Canfield SE, Hassen WA et al (2003) IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther 7(2):185-192 (Pubitemid 36395353)
40. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S (2011) Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 117(20):5381-5390
41. Nonaka K, Saio M, Suwa T et al (2008) Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes. J Leukoc Biol 84(3):679-688